The Patent Finder

Terms ending in 2040

Ablynx N.V.

Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,578,129LRP5 and PD-1 Antagonist Anticancer Combination Therapy
In force
 · High confidence
Ablynx N.V.In forceHigh confidence
US 11,332,525Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting Tnfa and IL-23
In force
 · High confidence
SanofiIn forceHigh confidence
US 11,208,476Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting IL-13 and TSLP
In force
 · High confidence
Ablynx N.V.In forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Ablynx N.V..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited